Kristin Kaasen Jørgensen
- Associate professor; MD, PhD
Publications 2024
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Lancet Rheumatol, 6 (4), e226-e236
DOI 10.1016/S2665-9913(23)00341-7, PubMed 38402891
Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study
Front Immunol, 15, 1296273
DOI 10.3389/fimmu.2024.1296273, PubMed 38455062
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
EBioMedicine, 108, 105317 (in press)
DOI 10.1016/j.ebiom.2024.105317, PubMed 39260039
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
RMD Open, 10 (2)
DOI 10.1136/rmdopen-2023-003545, PubMed 38599653
Publications 2023
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases
J Intern Med, 293 (5), 648-655
DOI 10.1111/joim.13616, PubMed 36843323
Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis
Nat Commun, 14 (1), 3304
DOI 10.1038/s41467-023-38840-8, PubMed 37280200
[The FIB-4 test as a decision-making tool]
Tidsskr Nor Laegeforen, 143 (5)
DOI 10.4045/tidsskr.23.0176, PubMed 36987901
[Primary sclerosing cholangitis]
Tidsskr Nor Laegeforen, 143 (17)
DOI 10.4045/tidsskr.23.0156, PubMed 37987062
A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation
Hepatology, 77 (3), 715-728
DOI 10.1002/hep.32773, PubMed 36056902
Reply: The mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. Is the dysbiosis index really predictive for the recurrence of PSC?
Hepatology, 77 (6), E188-E189
DOI 10.1097/HEP.0000000000000340, PubMed 36815351
Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type
Scand J Gastroenterol, 58 (8), 874-882
DOI 10.1080/00365521.2023.2177884, PubMed 36788656
HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis
Clin Gastroenterol Hepatol, 21 (12), 3019-3029.e5
DOI 10.1016/j.cgh.2023.03.044, PubMed 37061107
T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
JCI Insight, 8 (12)
DOI 10.1172/jci.insight.165111, PubMed 37159281
Publications 2022
Impact on follow-up strategies in patients with primary sclerosing cholangitis
Liver Int, 43 (1), 127-138
DOI 10.1111/liv.15286, PubMed 35535655
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia
Scand J Gastroenterol, 58 (1), 25-33
DOI 10.1080/00365521.2022.2108684, PubMed 35996928
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
Lancet Rheumatol, 5 (1), e36-e46
DOI 10.1016/S2665-9913(22)00330-7, PubMed 36415604
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
J Intern Med, 292 (3), 477-491
DOI 10.1111/joim.13495, PubMed 35411981
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study
BMC Med, 20 (1), 378
DOI 10.1186/s12916-022-02587-8, PubMed 36199139
Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Gastroenterology, 163 (4), 937-949.e2
DOI 10.1053/j.gastro.2022.06.052, PubMed 35753383
Algebraic topology-based machine learning using MRI predicts outcomes in primary sclerosing cholangitis
Eur Radiol Exp, 6 (1), 58
DOI 10.1186/s41747-022-00312-x, PubMed 36396865
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
RMD Open, 8 (2)
DOI 10.1136/rmdopen-2022-002417, PubMed 36328399
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy
Arthritis Rheumatol, 74 (8), 1321-1332
DOI 10.1002/art.42153, PubMed 35507355
[We need a new strategy for liver disease]
Tidsskr Nor Laegeforen, 142 (3)
DOI 10.4045/tidsskr.21.0892, PubMed 35170917
Publications 2021
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
Lancet Rheumatol, 4 (3), e177-e187
DOI 10.1016/S2665-9913(21)00394-5, PubMed 34977602
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 325 (17), 1744-1754
DOI 10.1001/jama.2021.4172, PubMed 33944876
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 326 (23), 2375-2384
DOI 10.1001/jama.2021.21316, PubMed 34932077
[Diagnosis and treatment of autoimmune hepatitis]
Tidsskr Nor Laegeforen, 141 (10)
DOI 10.4045/tidsskr.20.1045, PubMed 34182737
Publications 2020
Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway
PLoS One, 15 (3), e0230263
DOI 10.1371/journal.pone.0230263, PubMed 32163489
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
Clin Gastroenterol Hepatol, 18 (10), 2295-2304.e2
DOI 10.1016/j.cgh.2020.02.014, PubMed 32068151
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
BioDrugs, 34 (5), 681-694
DOI 10.1007/s40259-020-00438-7, PubMed 32965617
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
Trials, 21 (1), 13
DOI 10.1186/s13063-019-3734-4, PubMed 31907007
Publications 2019
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
J Intern Med, 285 (6), 653-669
DOI 10.1111/joim.12880, PubMed 30762274
Publications 2018
Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease
Hepatol Commun, 2 (8), 956-967
DOI 10.1002/hep4.1200, PubMed 30094406
Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study
Scand J Gastroenterol, 53 (3), 297-304
DOI 10.1080/00365521.2017.1421705, PubMed 29301479
Publications 2017
Experience with Biosimilar Infliximab (Remsima®) in Norway
Dig Dis, 35 (1-2), 83-90
DOI 10.1159/000449088, PubMed 28147374
Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply
Lancet, 390 (10111), 2436
DOI 10.1016/S0140-6736(17)32463-7, PubMed 29208304
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Lancet, 389 (10086), 2304-2316
DOI 10.1016/S0140-6736(17)30068-5, PubMed 28502609
Publications 2016
Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease
J Hepatol, 66 (1), 116-122
DOI 10.1016/j.jhep.2016.09.002, PubMed 27647428
A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency
Am J Gastroenterol, 111 (10), 1467-1475
DOI 10.1038/ajg.2016.329, PubMed 27527747
No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis
Clin Gastroenterol Hepatol, 14 (12), 1806-1812
DOI 10.1016/j.cgh.2016.07.032, PubMed 27521513
Publications 2015
Characterization of Intestinal Microbiota in Ulcerative Colitis Patients with and without Primary Sclerosing Cholangitis
J Crohns Colitis, 10 (3), 330-7
DOI 10.1093/ecco-jcc/jjv204, PubMed 26526357
Publications 2013
Colectomy for patients with ulcerative colitis and primary sclerosing cholangitis - what next?
J Crohns Colitis, 8 (5), 421-30
DOI 10.1016/j.crohns.2013.10.008, PubMed 24239402
Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease
Clin Gastroenterol Hepatol, 11 (5), 517-23
DOI 10.1016/j.cgh.2012.12.027, PubMed 23333218
Publications 2012
Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study
Scand J Gastroenterol, 47 (8-9), 1021-9
DOI 10.3109/00365521.2012.685754, PubMed 22577871
Publications 2011
Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients
Inflamm Bowel Dis, 18 (3), 536-45
DOI 10.1002/ibd.21699, PubMed 21456044
Publications 2010
Paucity of mycobacteria in mucosal bowel biopsies from adults and children with early inflammatory bowel disease
J Crohns Colitis, 4 (5), 561-6
DOI 10.1016/j.crohns.2010.05.003, PubMed 21122560